On September 2, Intuitive Surgical rose 3.08% in regular trading, trading at $380.38/share, with turnover of approximately $48.93 million. The move was supported by a combination of recent investment bank upgrades and a broader healthcare equipment sector rebound.

On the news front, Oppenheimer upgraded Intuitive Surgical from Market Perform to Outperform on August 12, setting a price target of $500. The firm noted that competitors face unique workflow challenges and real estate issues that limit their long-term appeal, while customized price-volume contracts complicate competitive returns. Earlier, UBS also initiated a Buy rating with a $500 target. The analyst consensus currently stands at an average overweight rating with a mean price target of approximately $480.

Fundamentally, the company reported strong Q2 results with revenue of $2.89 billion and adjusted EPS of $2.80, beating estimates of $2.82 billion and $2.50 respectively. Global da Vinci procedure volume grew 15% year-over-year, with installed base reaching 11,710 systems. Meanwhile, the broader Health Care Equipment sector rallied in tandem, with Boston Scientific up 2.75%, Abbott up 1.96%, Medtronic up 1.76%, and Stryker up 0.96%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)